Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases including Alzheimer's and Parkinson's.

Muna Therapeutics

Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 and based in Copenhagen, Denmark. 

Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. These disorders impact memory, movement, language, behavior and personality resulting in disability and death of millions of patients around the globe. 

We focus our groundbreaking science on identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases.  Our name reflects this focus:  Muna means ‘to remember’ in Old Norse. 

Michael J. Fox Foundation

Sanofi Ventures

Novo Holdings

Polaris Partners

Droia Ventures

Sofinnova Partners

LS Polaris Innovation Fund

LSP BioVentures

V-Bio Ventures

We are recruiting for two Research Associates to join #Muna_Therapeutics' MiND-MAP team in #Leuven, #Belgium.  MiND-MAP is our innovative, all-in-human drug target discovery and validation platform.  MiND-MAP utilizes spatial transcriptomics from postmortem brain samples to understand cellular and molecular responses to misfolded protein and other pathologies and advance these insights into novel drug targets. The role description and how to apply are in the document below. #muna_tx #neurodegeneration #neuroinflammation #Alzheimers #biotech

I am presenting new insights into Kv1.3 blockers as therapeutics for #Parkinson’s and progressive #MS (poster #445) and the impact of MiND-MAP (#151), Muna Therapeutics  all-in-human #alzheimers target mining and validation platform, at #ADPD2024. Also visit our poster on TREM2 agonists (#147)

CEOs of some of the hottest and most innovative companies in CNS Neuroscience drug development are speaking at Bio-Neuroscience. Join them at the summit for leading CEOs, investors and industry. #BioNeuroscience bio-neuroscience.com Niels Plath Muna Therapeutics Broadreach Global Amsterdam UMC Amsterdam UMC - Amsterdam Neuroscience Andrea Soto Padilla Pieter van Bokhoven Paweł Świeboda Naomi Glover, MSc, FRSA, FRSPH European Brain Council

Niels Plath, Muna Tx’s CSO, will be speaking about our work on next generation therapeutics for neurodegenerative diseases at Bio-Neuroscience in Amsterdam.

As we advance our work to the clinic to bring patients therapeutic options for #neurodegenerativediseases, we at Muna Therapeutics have serious fun, every day - check out the video clip below! #muna_tx #neuroscience #neurodegeneration  #alzheimersdisease #parkinsonsdisease #multiplesclerosis #biotech #neurology

MUNA

COM:MUNATHERAPEUTICS

Muna Therapeutics

locale

market

industry

website

linkedin

investor of

competitor of

Metrics